News

Novartis, Amgen and Banner Alzheimer's Institute remain committed after discontinuation of two Generation Program studies

11 July 2019 – Novartis, Amgen and Banner Alzheimer's Institute have announced the discontinuation of investigation of the BACE1 inhibitor CNP520 (umibecestat) in two Phase II/III studies. [read more]

Dementia and healthy ageing given prominent focus at the G20

4 July 2019 – Dementia was specifically recognised as a global health priority by G20 leaders in the declaration of the Osaka Summit this weekend. ADI worked hard for this to happen and it will provide much needed global attention from G20 countries. [read more]

Canadian government launches national plan to tackle dementia

17 June 2019 – The government of Canada today adopted a national plan on dementia. The plan is the 32nd to be adopted worldwide, and includes key targets for improving awareness, access to care, support and treatment, research and risk reduction of dementia by 2025. [read more]

New ADI report on the 2nd anniversary of the Global plan on dementia calls for urgent action

21 May 2019 – ADI's new report, From Plan to Impact II: the urgent need for action, has been published to mark the 2nd anniversary of the adoption of the World Health Organization (WHO) Global plan on the public health response to dementia 2017-2025. [read more]

Queen Sofía of Spain awarded for becoming Global Ambassador

15 May 2019 – ADI's Chief Executive Paola Barbarino presented Her Majesty Queen Sofía of Spain with an award for becoming ADI’s Global Ambassador at the 3rd Dementia Forum X meeting at the Royal Palace of Stockholm. [read more]

ADI, GADAA and Alzheimer's Pakistan launch report on Dementia in Humanitarian Settings

9 May 2019 – A pioneering new report by ADI, The Global Alzheimer’s & Dementia Action Alliance (GADAA) and Alzheimer's Pakistan has revealed that people with dementia are being ignored in times of humanitarian crisis. [read more]

A new type of dementia identified?

3 May 2019 - A paper published in the journal Brain (30 April 2019) has identified a brain disorder that appears to mimic the clinical features of Alzheimer’s disease. Known as LATE (Limbic-predominant Age-related TDP-43 Encephalopathy) it appears to be linked to the accumulation of a protein, TDP-43, in the brain, while Alzheimer's disease is more commonly linked to two other brain proteins - amyloid and tau. [read more]

Queen Silvia of Sweden awarded for becoming Global Ambassador

3 April 2019 – ADI's Chief Executive Paola Barbarino presented Her Majesty Queen Silvia of Sweden with an award for becoming ADI’s Global Ambassador at the Jubilee event for the Queen Silvia Nursing Award at the Royal Palace of Stockholm. [read more]

Biogen and Eisai remain committed after discontinuation of ENGAGE and EMERGE programmes

22 March 2019 – Pharmaceutical companies Biogen and Eisai have announced the discontinuation of two Phase 3 trials of aducanumab. The decision came after analysis by an independent monitoring committee indicated the trials were unlikely to succeed. Biogen and Eisai will continue to investigate other treatments for Alzheimer’s disease, including anti-amyloid treatment BAN2401. [read more]

Global Perspective Newsletter for February 2019

The February 2019 edition of our Global Perspective Newsletter is now available. Read the latest news from ADI, our partners and member associations, including updates from the WHO Executive Board; the Korean National Institute (KNID)'s symposium; Dementia Alliance International, and much more. [read it now]